The Journal of Immunology, Vol 142, Issue 6 2041-2045, Copyright © 1989 by American Association of Immunologists

ARTICLES

Synthesis and regulation of C1 inhibitor in human skin fibroblasts

Y Katz and RC Strunk
Division of Pulmonary and Allergy/Immunology, St. Louis Children's Hospital, MO.

Proteins of the C1 complex, C1q, C1r, and C1s, of the classical pathway of complement activation are known to be synthesized in human skin fibroblasts. Using metabolic labeling with [35S]methionine, immunoprecipitation, and SDS-PAGE, we demonstrate that human skin fibroblasts synthesize and secrete C1 inhibitor with an apparent molecular mass of 78 kDa in the cell lysate and 102 kDa in the extracellular medium. This C1 inhibitor had the capacity to bind activated C1s. Fibroblasts synthesized 30- to 50-fold more C1 inhibitor than was synthesized in monocytes. As previously reported, fibroblasts also synthesized C1r and C1s. IFN-gamma, IFN-beta 1, and TNF had significant, but distinct, effects on synthesis of C1 inhibitor, C1r, and C1s. Incubation of the cells with IFN-gamma, 1000 U/ml, for 24 h induced increases in the synthesis of C1 inhibitor, C1r, and C1s by 4.2- , 1.9- and 1.6-fold, respectively. IFN-beta 1 had effects similar to IFN-gamma, although smaller in magnitude. TNF, 12.5 ng/ml, induced increases in the synthesis of C1 inhibitor, C1r, and C1s by 1.5-, 1.4- and 2.6-fold. IL-1, IFN-beta 2 (IL-6), and LPS did not affect synthesis of C1 inhibitor, C1r, or C1s. Fibroblasts are present in large amounts in most tissues. Synthesis of C1 inhibitor, C1r, and C1s by these cells could provide a source of these important proteins in body tissues. In addition, fibroblasts should be a good model for the in vitro study of genetic diseases involving the synthesis of these proteins.

This article has been cited by other articles:

				G. Vinci, N. J. Lynch, C. Duponchel, T.-M. Lebastard, G. Milon, C. Stover, W. Schwaeble, and M. Tosi In Vivo Biosynthesis of Endogenous and of Human C1 Inhibitor in Transgenic Mice: Tissue Distribution and Colocalization of Their Expression J. Immunol., November 15, 2002; 169(10): 5948 - 5954. [Abstract] [Full Text] [PDF]

				C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]

				M.-L. Lokki, A. Circolo, P. Ahokas, K. L. Rupert, C. Y. Yu, and H. R. Colten Deficiency of Human Complement Protein C4 Due to Identical Frameshift Mutations in the C4A and C4B Genes J. Immunol., March 15, 1999; 162(6): 3687 - 3693. [Abstract] [Full Text] [PDF]

				K. Nakagawa, H. Sakiyama, T. Tsuchida, K. Yamaguchi, T. Toyoguchi, R. Masuda, and H. Moriya Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody Ann Rheum Dis, March 1, 1999; 58(3): 175 - 181. [Abstract] [Full Text]